Oslo, Norway, 19 December 2007
Clavis Pharma ASA has entered into a Market Maker Agreement with ABG Sundal Collier Norge ASA.
The investment bank ABG Sundal Collier Norge ASA will from 20 December 2007 quote bid and ask prices in the Clavis Pharma share in accordance with guidelines provided by the Oslo Stock Exchange. The purpose of the agreement is to increase the trading liquidity of the Clavis Pharma share.
For further information, please contact
Gunnar Manum
Chief Financial Officer
Clavis Pharma ASA
Tel: +47 24 11 09 50
About Clavis Pharma
Clavis Pharma ASA is an oncology focused pharmaceutical company using its proprietary Lipid Vector Technology (LVT) platform
to create New Chemical Entities (NCEs), by significantly improving already established drugs. The improvements are achieved
by chemically binding specific unsaturated lipids to existing, and well understood, approved pharmaceuticals. Data generated
suggests the resulting patentable NCEs offer improved efficacy and reduced side effects through enhanced pharmacokinetic properties,
greater tissue penetration and, in many cases, additional modes of action.
Clavis Pharma's objective is to develop its drug candidates until significant value has been created and proof of principle in man has been shown. For further clinical development and commercialisation of the products, Clavis Pharma will enter into strategic partnerships with established pharmaceutical or biotech companies. The company's product portfolio includes three new cancer drugs, of which the first ELACYTTM, is in Clinical Phase II, the second, CP-4126, is in Clinical Phase I, and the third, CP-4200, is in Preclinical Development. Results indicate that these products have promising potential for several cancer indications within solid tumours and leukaemia.
The shares of Clavis Pharma ASA are listed on the Oslo Stock Exchange (ticker: CLAVIS). Additional information on Clavis Pharma can be found at: www.clavispharma.com